Clinical Trial Detail

NCT ID NCT02723994
Title A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Incyte Corporation
Indications

acute lymphocytic leukemia

Therapies

Prednisone

Dexamethasone + Doxorubicin

Leucovorin

Mercaptopurine + Thioguanine

Asparaginase + Cytarabine

Ruxolitinib

Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase

Age Groups: adult child

Additional content available in CKB BOOST